Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Certara Inc (CERT)

Certara Inc (CERT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,226,040
  • Shares Outstanding, K 160,841
  • Annual Sales, $ 354,340 K
  • Annual Income, $ -55,360 K
  • 60-Month Beta 1.52
  • Price/Sales 6.20
  • Price/Cash Flow 14.63
  • Price/Book 2.10
Trade CERT with:

Options Overview Details

View History
  • Implied Volatility 77.30% ( +10.32%)
  • Historical Volatility 45.66%
  • IV Percentile 67%
  • IV Rank 56.63%
  • IV High 136.18% on 06/21/24
  • IV Low 0.40% on 10/26/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 13
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 656
  • Open Int (30-Day) 653

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.07
  • Number of Estimates 3
  • High Estimate 0.07
  • Low Estimate 0.06
  • Prior Year 0.10
  • Growth Rate Est. (year over year) -30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.04 +9.05%
on 06/21/24
17.40 -18.28%
on 06/06/24
-3.12 (-17.99%)
since 06/05/24
3-Month
13.04 +9.05%
on 06/21/24
19.18 -25.86%
on 04/09/24
-3.93 (-21.65%)
since 04/05/24
52-Week
11.81 +20.41%
on 11/01/23
19.87 -28.44%
on 03/08/24
-4.39 (-23.59%)
since 07/05/23

Most Recent Stories

More News
Are These 3 Small Momentum Stocks Setting Up Big Gains?

MINISO, PDF Solutions, and Certara are small stocks with strong price momentum. It’s not unusual for small stocks to show more price momentum than larger peers.

MNSO : 18.19 (-3.24%)
PDFS : 36.37 (+0.83%)
CERT : 14.22 (+2.75%)
RBA : 77.00 (-0.36%)
Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal

Xentria, Inc., a biotech company focused on developing treatments to address unmet clinical needs, today announced the peer reviewed publication in Frontiers in Pharmacology of a biosimulation model...

CERT : 14.22 (+2.75%)
Why Certara's Shares Rose 37.7% This Week

The company, which helps other companies in their drug development, reported strong third-quarter numbers.

CERT : 14.22 (+2.75%)
Certara, Inc. (CERT) Q2 2022 Earnings Call Transcript

CERT earnings call for the period ending June 30, 2022.

CERT : 14.22 (+2.75%)
Certara Reports Second Quarter 2022 Financial Results

Biosimulation software and services fuel second quarter growth...

CERT : 14.22 (+2.75%)
Certara Introduces Update of Pinnacle 21â„¢ Enterprise and New Pinnacle 21â„¢ Data Exchange Module

New automation, analytics and collaboration features save time and ensure regulatory compliance...

CERT : 14.22 (+2.75%)
Certara Appoints Rosemary Crane as New Independent Board Member

PRINCETON, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of...

CERT : 14.22 (+2.75%)
Certara Introduces New Simcypâ„¢ Discovery Simulator for Early-Stage and Translational Drug Development

Advances lead optimization, first-in-human dose prediction and formulation development...

CERT : 14.22 (+2.75%)
Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics

New capabilities enhance clinical predictability for different compounds across more therapeutic areas...

CERT : 14.22 (+2.75%)
Certara, Inc. (CERT) Q1 2022 Earnings Call Transcript

CERT earnings call for the period ending March 31, 2022.

CERT : 14.22 (+2.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Certara Inc. provides medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Certara Inc. is based in NJ, United States.

See More

Key Turning Points

3rd Resistance Point 14.95
2nd Resistance Point 14.61
1st Resistance Point 14.41
Last Price 14.22
1st Support Level 13.87
2nd Support Level 13.53
3rd Support Level 13.33

See More

52-Week High 19.87
Fibonacci 61.8% 16.79
Fibonacci 50% 15.84
Fibonacci 38.2% 14.89
Last Price 14.22
52-Week Low 11.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar